Please login to the form below

Not currently logged in
Email:
Password:

Dr Georg Buchner joins Silence Therapeutics

He assumes a business development role at the London-based biotech

London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development.

He was formerly VP of Corporate & Business Development at Novacta Biosystems and prior to that served as business development director at Haptogen. During that time he was instrumental in the sale of the Haptogen business to Wyeth, now part of Pfizer, in 2007

At Silence Georg will work with Tony Sedgwick, who was appointed chief business officer in September, as part of the company's strategy to continue to broaden its collaborations with global pharmaceutical and biotechnology companies.

Silence's CEO Thomas Christély said: "We are pleased to welcome Dr Georg Buchner to Silence. Georg has a strong track record in business development and his experience will strengthen our growing business development team as we seek to expand our increasing list of corporate partnerships.”

10th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics